Optimal treatment for Siewert type II and III adenocarcinoma of the esophagogastric junction: A retrospective cohort study with long-term follow-up

Table 4 Prognostic analysis in patients with adenocarcinoma of the esophagogastric junction

Category	Classification	Univariate analysis				Multivariate analysis
		n	Proportion	5 yr-OS	P value	HR	95%CI	P value
Age (yr)	< 65	29	35%	67%	0.084			0.47
	≥ 65	54	65%	52%
Sex	Male	65	78%	56%	0.57
	Female	18	22%	67%
Siewert type	II	62	75%	58%	0.88
	III	21	25%	57%
Esophageal invasion	≤ 3 cm	73	88%	60%	0.21
	> 3 cm	10	12%	40%
Tumor size	< 6 cm	45	54%	58%	0.86
	≥ 6 cm	38	46%	58%
pT	pT1-2	24	29%	77%	0.01a			0.88
	pT3	59	71%	50%
pN	pN0	25	30%	78%	0.028a			0.30
	pN1-3	58	70%	49%
Mediastinal LN meta	No	78	94%	60%	0.007a			0.17
	Yes	5	6%	20%
LNR	< 0.16	59	71%	71%	< 0.001a			0.001a
	> 0.16	24	29%	23%		4.29	1.79-10.89
ly	ly0, 1	29	35%	69%	0.059			0.13
	ly2, 3	54	65%	52%
v	v0, 1	27	33%	83%	< 0.001a			0.004a
	v2, 3	56	67%	46%		5.99	1.71-24.90
Histopathological Grade	G1 + G2	48	58%	60%	0.28
	G3 + G4	35	42%	55%
Adjuvant chemotherapy	No	54	65%	56%	0.52
	Yes	29	35%	61%
Residual tumor	R0	74	89%	62%	< 0.001a			0.056
	R1	9	11%	22%		2.61	0.97-6.59

AEG: Adenocarcinoma of the esophagogastric junction; OS: Overall survival; HR: Hazard ratio; LNR: Lymph node ratio; ly: Lymphatic invasion; v: Venous invasion.

^aP < 0.05.